-
It is advisable to use it as soon as possible! SGLT-2i can reduce the risk of "atrial fibrillation" in elderly diabetics
Time of Update: 2023-01-07
Recently, the first clinical practice survey study published in JAMA Network Open on the risk of atrial fibrillation (AF) in the treatment of elderly patients with type 2 diabetes mellitus with antidiabetic drugs SGLT2 inhibitors found that sodium glucose was used compared with dipeptidyl peptidase IV (DPP-4i) in elderly patients with type 2 diabetes The risk of AF with co-transporter-2 inhibitors (SGLT-2is) was significantly reduced by 18%.
-
Identify this high-risk "code" as early as possible, for non-alcoholic fatty liver disease say no!
Time of Update: 2022-09-15
, with a cumulative impact factor of 500 and more than 2,000 citationsFor medical professionals onlyThe latest research of Professor Wang Guang's team deciphers the high-risk identification code for non-alcoholic fatty liver diseaseAIP is closely related to NAFLD, early screening and early preventionWhy should we prevent NAFLD as early as possible?Obesity (51.
-
Covestro points to heightened risks to gas supply, possible production cuts
Time of Update: 2022-08-16
Covestro said it expects a "more challenging" second half of the year and expects Russia's war against Ukraine to continue to affect global supply chains, already high energy and raw material prices, high inflation and a slowdown in global economic growth.
-
Adolescents and young cancer survivors should be alert to the possibility of a 60% increase in the risk of secondary tumors
Time of Update: 2021-11-15
In addition, more and more studies have found that adolescents and young adult cancer survivors have a higher risk of cancer recurrence, including cancer recurrence and secondary malignancies (SMN, which is different from the first primary tumor).
-
Briefing on October 13, 2021: The new crown vaccine can reduce the risk of hospitalization by 90
Time of Update: 2021-10-19
manageA document published on the FDA website stated: “Some effectiveness studies on actual conditions indicate that over time, the effectiveness of Moderna vaccine against asymptomatic infections or against delta variants is declining, while others The research by the United States did not show such a conclusion .